View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
May 21, 2020

Long-acting anti-retroviral drug cabotegravir more effective than Truvada for prevention of HIV

By Victoria Smith

Cabotegravir, a long-acting injectable antiretroviral drug being developed by the National Institute of Allergy and Infectious Diseases (NIAID) as a potential for pre-exposure prophylaxis (PrEP) in patients at risk of catching human immunodeficiency virus (HIV), could be more desirable than Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), the currently approved PrEP.

Cabotegravir is intended as a two-monthly injection, showing satisfactory protection against catching HIV in a large-scale study ultimately disrupted by the current global Covid-19 pandemic. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena